Department of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX, United States.
Department of Immunology, Tufts University School of Medicine, Boston, MA, United States.
Front Immunol. 2022 Nov 18;13:1070424. doi: 10.3389/fimmu.2022.1070424. eCollection 2022.
is a nosocomic opportunistic Gram-negative bacteria known for its extensive drug-resistant phenotype. hospital-acquired infections are major contributors to increased costs and mortality observed during the COVID-19 pandemic. With few effective antimicrobials available for treatment of this pathogen, immune-based therapy becomes an attractive strategy to combat multi-drug resistant infection. Immunotherapeutics is a field of growing interest with advances in vaccines and monoclonal antibodies providing insight into the protective immune response required to successfully combat this pathogen. This review focuses on current knowledge describing the adaptive immune response to , the importance of antibody-mediated protection, developments in cell-mediated protection, and their respective therapeutic application going forward. With 's increasing resistance to most current antimicrobials, elucidating an effective host adaptive immune response is paramount in the guidance of future immunotherapeutic development.
是一种医院获得性机会性革兰氏阴性细菌,以其广泛的耐药表型而闻名。医院获得性感染是导致 COVID-19 大流行期间成本增加和死亡率上升的主要因素。由于治疗这种病原体的有效抗菌药物很少,免疫疗法成为对抗多药耐药 感染的一种有吸引力的策略。免疫疗法是一个日益受到关注的领域,疫苗和单克隆抗体的进步为成功对抗这种病原体所需的保护性免疫反应提供了深入了解。本综述重点介绍了目前对 的适应性免疫反应的描述,抗体介导的保护的重要性,细胞介导的保护的发展,以及它们未来的治疗应用。随着 的耐药性越来越强,大多数当前的抗菌药物,阐明有效的宿主适应性免疫反应是未来免疫治疗发展的关键。